Qiagen (NYSE:QGEN) Rating Lowered to “Hold” at DZ Bank

Qiagen (NYSE:QGEN) was downgraded by investment analysts at DZ Bank from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks reports.

Other equities analysts have also issued reports about the company. Morgan Stanley restated an “overweight” rating on shares of Qiagen in a research report on Friday, September 11th. Barclays set a $40.00 price objective on Qiagen and gave the company an “equal weight” rating in a research note on Friday, August 7th. Kepler Capital Markets set a $38.60 target price on shares of Qiagen and gave the stock a “hold” rating in a report on Thursday, June 25th. Robert W. Baird lifted their target price on shares of Qiagen from $50.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, Stifel Nicolaus set a $40.00 price target on shares of Qiagen in a report on Friday, August 7th. Four research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $44.43.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $50.42 on Thursday. The stock has a market cap of $10.39 billion, a PE ratio of 25.83, a PEG ratio of 4.99 and a beta of 0.61. The company’s fifty day moving average is $44.44 and its 200 day moving average is $40.64. Qiagen has a 52 week low of $32.53 and a 52 week high of $57.81. The company has a quick ratio of 2.31, a current ratio of 2.85 and a debt-to-equity ratio of 0.48.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The business had revenue of $535.04 million during the quarter, compared to the consensus estimate of $527.50 million. During the same period in the previous year, the firm posted $0.60 earnings per share. The firm’s revenue for the quarter was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. Research analysts anticipate that Qiagen will post 2.44 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Engineers Gate Manager LP raised its holdings in shares of Qiagen by 107.7% during the second quarter. Engineers Gate Manager LP now owns 74,567 shares of the company’s stock valued at $2,916,000 after acquiring an additional 38,658 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in Qiagen in the first quarter worth $2,518,000. Baader Bank Aktiengesellschaft bought a new stake in Qiagen in the first quarter valued at $1,368,000. Public Employees Retirement System of Ohio bought a new stake in Qiagen in the second quarter valued at $2,836,000. Finally, WINTON GROUP Ltd bought a new stake in Qiagen in the second quarter valued at $1,423,000. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Trending Headlines about Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen updated third-quarter 2026 guidance to adjusted EPS of $0.65 and revenue of $548 million, above consensus estimates of $0.62 and $534.1 million, respectively. The figures are consistent with the company’s preliminary results and signal better-than-expected operating performance.
• Positive Sentiment: EQT agreed to acquire Qiagen in an all-cash transaction valued at approximately $12.1 billion, offering €46.50 per share. The takeover provides a defined valuation and has been unanimously accepted, with the transaction nearing completion. Qiagen to Be Acquired by EQT for $12.1 Billion in All-Cash Deal
• Positive Sentiment: Robert W. Baird raised its price target to $52 from $50 and upgraded the stock to “outperform,” citing potential value near the takeover consideration. Robert W. Baird Qiagen rating
• Neutral Sentiment: Unusually heavy call-option activity suggests increased short-term trading interest, with call purchases roughly doubling typical volume, but it does not establish a fundamental change in valuation.
• Neutral Sentiment: JPMorgan reaffirmed its “neutral” rating while lowering its price target to $52 from $55, leaving limited projected upside relative to the current trading level. JPMorgan Qiagen rating
• Negative Sentiment: Law firms Brodsky & Smith and Halper Sadeh announced investigations into whether Qiagen obtained a fair price for shareholders. Such reviews could create deal uncertainty, although they do not currently indicate that the transaction will be blocked. Brodsky & Smith shareholder investigation

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.